Markets · 1 sources covering this

AbbVie would gain an experimental eczema drug by buying biotech: report

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

MarketWatchCenter·3h ago
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
Read at MarketWatch →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/617a0e9a41c285fea25583730a0d06ad08d6c556"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="AbbVie would gain an experimental eczema drug by buying biotech: report"></iframe>

AbbVie would gain an experimental eczema drug by buying biotech: report

How 1 sources are covering this

AbbVie would gain an experimental eczema drug by buying biotech: report

More from Markets

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

You’re going to pay tax on RMDs — there’s no way around it. Or is there?

Social Security is looking at a $500-a-month cut. Could a new bipartisan commission make a difference?

Inside the push to weaken Washington’s toughest financial watchdog

Reader

Trust & legal

Across the network

How 1 sources are covering this

AbbVie would gain an experimental eczema drug by buying biotech: report

More from Markets

Scared to spend your retirement money? Here&#x2019;s one way to get over the fear of running out.

You&#x2019;re going to pay tax on RMDs &#x2014; there&#x2019;s no way around it. Or is there?

Social Security is looking at a $500-a-month cut. Could a new bipartisan commission make a difference?

Inside the push to weaken Washington&#x2019;s toughest financial watchdog

Reader

Trust & legal

Across the network

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

You’re going to pay tax on RMDs — there’s no way around it. Or is there?

Inside the push to weaken Washington’s toughest financial watchdog